Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197161 | 0.75 | DDB1 (0.42) | DDB1CRBNMAOAMAOBHTT | |
| SCHEMBL10352633 | 0.73 | DDB1 (0.40) | DDB1CRBNMAOAMAOBHTT | |
| SCHEMBL5552459 | 0.73 | DDB1 (0.59) | DDB1CRBNL3MBTL1ALDH1A1MMP2 | |
| SCHEMBL10611547 | 0.69 | DDB1 (0.62) | DDB1CRBNL3MBTL1ALDH1A1MMP2 | |
| SCHEMBL2361135 | 0.68 | DDB1 (0.77) | DDB1CRBNL3MBTL1ALDH1A1MMP2 | |
| SCHEMBL4528306 | 0.66 | DDB1 (0.51) | DDB1CRBNL3MBTL1ALDH1A1MMP2 | |
| SCHEMBL23705024 | 0.66 | ALDH1A1 (0.46) | MAOBALDH1A1MMP2MMP13 | |
| SCHEMBL11281090 | 0.66 | DDB1 (0.36) | DDB1CRBNMAOAMAOBL3MBTL1 | |
| SCHEMBL9251968 | 0.66 | TSHR (0.50) | L3MBTL1MMP13 | |
| SCHEMBL8624780 | 0.65 | CRBN (0.43) | DDB1CRBNMAOAMAOBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | SOLVAY S.A. (BE) | 2008-01-31 | — | — | US | disclosed |
| EP-1802595-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay SA (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037775-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay (Société Anonyme) (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | NPR3, VIP, NPPA | DDB1 4419/4885CRBN 2493/4885EPHX2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.